Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas

Miguel-Angel Gallego1, Bertrand Joseph, Therese H Hemström

  • 1INSERM U459, Faculté de Médecine 1, Place Verdun, Lille Cedex, France.

Oncogene
|August 3, 2004
PubMed

Insights

Non-small-cell lung cancer (NSCLC) cells resist conventional treatments but are sensitive to staurosporine (STS). Apoptosis-inducing factor (AIF) plays a key role in STS-induced cell death, independent of caspases.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncology

Background:

  • Non-small-cell lung carcinomas (NSCLCs) exhibit resistance to apoptosis induction via conventional anticancer therapies.
  • NSCLC cell lines demonstrate sensitivity to staurosporine (STS), a broad protein kinase inhibitor.

Purpose of the Study:

  • To investigate the mechanisms of STS-induced cell death in NSCLC cell line U1810.
  • To elucidate the roles of caspases and apoptosis-inducing factor (AIF) in STS-mediated apoptosis.

Main Methods:

  • Induction of apoptosis using STS in U1810 cells.
  • Assessment of mitochondrial release of AIF and cytochrome c (Cyt c).
  • Inhibition of caspases using z-VAD.fmk and evaluation of AIF's role via immunodepletion and antibody microinjection.

Main Results:

  • STS induced mitochondrial release of AIF and Cyt c, followed by caspase activation and cell death.
  • Caspase inhibition delayed but did not prevent STS-induced cell death or mitochondrial alterations.
  • AIF depletion or inhibition significantly reduced STS-induced nuclear condensation and cell death, while AIF overexpression enhanced it.

Conclusions:

  • Caspase activation is insufficient for U1810 cell death induction by STS.
  • The AIF-mediated mitochondrial death pathway plays a crucial role in STS-induced cell killing in NSCLC.

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...